Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring

Journal of Clinical Lipidology

Volumn 3, Issue 6, 2009, Pages 385-392

  McKenney, James ^a   Gandhi, Sanjay K ^b   Fox, Kathleen M ^c   Ohsfeldt, Robert L ^d  

^a National Clinical Research Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Atherosclerosis; LDL C; Lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEALTH CARE PLANNING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 71549173106     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.10.004     Document Type: Article

References (19)

1. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
3. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 46 (2005) 106-112
4. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-742
5. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
6. Dilaveris P., Giannopoulos G., Riga M., Synetos A., and Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 5 (2007) 227-237
7. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
8. Brown B.G., Hillger L., Zhao X.Q., Poulin D., and Albers J.J. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment Study. Ann NY Acad Sci 748 (1995) 407-417
9. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenosis assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived atheroma burden. Circulation 117 (2008) 2458-2466
10. Thompson G.R. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?. Atherosclerosis 131 (1997) 1-5
11. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., and ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 295 (2006) 1556-1565
12. Crouse III J.R., Raichlen J.S., Riley W.A., et al., METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
13. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
14. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
15. Ridker P.M., Danielson E., Fonseca F.A., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
16. Jensen L.O., Thayssen P., Pedersen K.E., et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 110 (2004) 265-270
17. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 110 (2004) 1061-1068
18. Fox K.M., Gandhi S.K., Ohsfeldt R.L., Blasetto J.W., and Davidson M.H. Effectiveness of statins in Medicare-eligible patients and patients <65 years using clinical practice data. Int J Clin Pract 61 (2007) 1634-1642
19. Kiechl S., Willeit J., and Bruneck Study Group. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 19 (1999) 1484-1490